MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$17,797K
EPS
-$0.11
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
15,152
9,941
4,266*
10,085
General and administrative
5,357
4,971
3,604*
3,831
Total operating expenses
20,509
14,912
7,870
13,916
Loss from operations
-20,509
-14,912
-7,870*
-13,916
Interest income, net
2,696
1,696
1,275*
2,101
Other (expense) income, net
-3
4
-17*
-2
Interest expense
-
-
0*
0
Total other income, net
2,693
1,700
1,257*
2,099
Loss before income taxes
-17,816
-13,212
-6,614*
-11,817
Income tax benefit
-19
-20
-10*
-15
Net loss
-17,797
-13,192
-6,604
-11,802
Basic EPS
-0.11
-0.09
-0.051
-0.08
Diluted EPS
-0.11
-0.09
-0.051
-0.08
Basic Average Shares
156,602,158
145,592,901
128,786,217
145,104,986
Diluted Average Shares
156,602,158
145,592,901
128,786,217
145,104,986
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$17,797K
(-44.68%↓ Y/Y)
Income tax benefit
-$19K
(9.52%↑ Y/Y)
Interest income, net
$2,696K
(91.61%↑ Y/Y)
Loss before income
taxes
-$17,816K
(-44.59%↓ Y/Y)
Total other income,
net
$2,693K
(92.36%↑ Y/Y)
Other (expense)
income, net
-$3K
(57.14%↑ Y/Y)
Loss from operations
-$20,509K
(-49.46%↓ Y/Y)
Total operating
expenses
$20,509K
(49.46%↑ Y/Y)
Research and development
$15,152K
(61.38%↑ Y/Y)
General and
administrative
$5,357K
(23.63%↑ Y/Y)
Buy us a coffee
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)